June 8-9, 2015 - Nice, France


Get Adobe Flash player

Monday June 8
08.30   Opening remarks
    M. Amor, N. Cheshire, E. Ducasse, M. Lachat, N. Mangialardi, P. Schneider,
I. Van Herzeele
08.35   BTK strategies and best options
    Moderators: R. Ferraresi, A. Sauguet, E. Ducasse
    State of the art of BTK-CLI treatment
    08.35   Arterial status, angiosome, arterial calcifications, is it possible to plan treatment at BTK level? M. Gargiulo
    08.43   Big vessel versus small vessel disease:
what is the true cause of critical limb ischemia? R. Ferraresi
    08.51   BTK long lesions: devices and optimaltreatment, R. Ferraresi
    08.59   Insight about ultrasound in planing, access and control of BTK angioplasty,
E. Puras Mallagray
    09.07   BTK bifurcations: best treatment, F. Airoldi
    09.15   Discussion
        State of the art:
    09.20   Drug eluting stent in BTK disease, K. Deloose
    09.28   Bare metal stent in BTK disease, E. Ducasse
    09.36   Drug eluting balloon in BTK disease, K. Deloose
    09.44   Distal bypass in BTK disease, P. Schneider
    09.56   Discussion, M. Di Primio
    10.00   Coffee break in the exhibition hall
    Tips & tricks & complications
    10.30   Challenging BTK case, E. Ducasse
    10.40   When coronary devices could help? A. Sauguet
    10.50   Below-the-ankle angioplasty and stenting for CLI, J. Brunet
    11.00   Extreme distal revascularization with conventional and alternative techniques,
M. Di Primio
    11.10   Discussion
11.20   Thoracic pathology
    Moderators: S. Ronchey, F. Veith, A. Bray
    How I deal with the aortic arch:
from planning to follow-up
    11.20   My experience in ascending aorta TEVAR, I. Loftus
    11.28   Open surgery conventional: discrepancy in results (lights and shadow),
D. Pacini
    11.36   Ascending aorta: is the endovascular approach realistic? T. Kölbel
    11.44   Off the shelf solution: selection based on planning, N. Mangialardi
    11.52   My planing for arch Chimney, J. Brunkwall
    12.00   Endoleak after arch Chimney, R. Kolvenbach
    12.08   Hybrid repair: technique for total debranching, P. Bergeron
    12.16   Stroke rate and mortality in arch procedures, M. Lachat
    12.24   Endovascular arch repair following ascending aorta open surgery, T. Kölbel
    12.32   Complications of supraaortic debranching, S. Ronchey
    12.40   Demonstration (crazy arch case), T. Larzon
    12.48   Discussion
    13.00   Buffet lunch served on the rooftop, coffee served in the exhibition hall
14.00   Thoracic pathology
    Moderators: J. Busquet, F. Veith, M. Lachat, N. Mangialardi
    14.00   We do treat all - and why, N. Cheshire
    14.08   I do treat when appropriate, J. Steuer
    14.16   The false channel occlusion technique, T. Kölbel
    14.24   TEVAR for chronic dissection, I. Loftus
    14.32   News from imaging will change our attitude, L. Maene
    14.40   Discussion
    Descending aorta
    14.50   TEVAR European guidelines, V. Riambau
    14.58   How I fix endoleak in TEVAR, P. Kasprzak
    15.06   Clampless sutured anastomosis technique, Z. Rancic
    15.14   Long-term results for TEVAR after BAI, R. Vallabhaneni
    15.22   Access vessels challenges and best access route, F. Setacci
    15.30   Discussion
15.45   Highly complex lesions in femo/pop.
What do I learn from my daily practice ?
    15.45   Clinical case review, J. Brunet
    15.57   Clinical case review, M. Amor
    16.09   Discussion
    16.15   Coffee break in the exhibition hall
16.45   Femoropopliteal disease - Part 1
    Moderators: Y. Gouëffic, K. Deloose, P. Schneider, C. Setacci
    16.45   Anti-platelet therapy: who needs it and what to prescribe, K. Deloose
    16.53   Popliteal artery aneurysm - What is the best mode of treatment? T. Schmitz Rixen
    17.01   Radial access for femoropopliteal lesions: tips and tricks, R. Coscas
    17.09   Closure devices: treatment of complications, J. Van Den Berg
    17.18   Discussion
    TASC A/B femoropopliteal lesions
    17.20   Is connected stent the good option for TASC A/B SFA lesions?
E. Ducasse
    17.30   Discussion
        Debate. TASC A/B femoropopliteal lesions treatment
        17.35 Stent should be the first line treatment, J-P. de Vries
        17.43 Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery (ILLUMENATE FIH Trial), Y. Gouëffic
        17.51 DES should be the first line treatment, J. Van Den Berg
        17.59 Discussion
    18.05   Are current stents ready for the « surgical landing-zones »? L. Maene
    18.13   Lecture from China: Selective stent placement versus balloon angioplasty for
renovascular hypertension caused by Takayasu Arteritis: two-year results,
X. Jiang
    18.21   End of the sessions